Copyright © 2004 by the European Society of Cardiology.
Clinical research
Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial
a Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London SW3 6LY, UK
b Division of Cardiology, University of Michigan School of Medicine, USA
c Division of Applied Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
* Corresponding author. Tel.: +44-207-351-8203; fax: +44-207-351-8733
E-mail address: s.anker{at}imperial.ac.uk
Received 18 February 2003; revised 2 March 2004; accepted 2 April 2004
Abstract
Aims The correction of anaemia in chronic heart failure (CHF) has been suggested to be associated with an improvement in symptoms and cardiac function. We aimed to investigate the relationship between the concentration of haemoglobin and survival in CHF.
Methods and results We analysed haemoglobin concentrations in 3044 patients recruited in the Evaluation of Losartan In The Elderly (ELITE II) trial. Patients of mean age 71.5±6.8 years (±SD) and New York Heart Association (NYHA) class 2.5±0.6 were enrolled from June 1997 to May 1998 and followed-up for survival (range 1–780 days, median 551). In univariate analysis, age, NYHA class, serum creatinine, left ventricular ejection fraction (all 
) and sex (
) all predicted survival. Haemoglobin as a continuous variable for all patients was not a significant prognostic marker (
). However, sub-dividing patients according to 1.0 g/dL increments of haemoglobin revealed that the survival relationship was non-linear. The results from the polynomial regression suggest that the optimal interval is a symmetric one centred around 14.5 g/dL. This was independent of age, sex, NYHA class, left ventricular ejection fraction, creatinine, co-existing chronic obstructive pulmonary disease and treatment allocation (
). There was a minor fall in plasma haemoglobin at the 12-month follow-up (mean change for all patients 0.3±2.2 g/dL, ), with no difference between captopril and losartan groups (
).
Conclusion Haemoglobin is an independent predictor of mortality in CHF patients, with anaemic and polycythaemic patients having the worst survival.
Key Words: Haemoglobin • Chronic heart failure • Survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Meer, D. J. Lok, J. L. Januzzi, P. W. B.-A. de la Porte, E. Lipsic, J. van Wijngaarden, A. A. Voors, W. H. van Gilst, and D. J. van Veldhuisen Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients Eur. Heart J., June 2, 2008; 29(12): 1510 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Toblli, A. Lombrana, P. Duarte, and F. Di Gennaro Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1657 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schwenger, C. Morath, and M. Zeier Use of Erythropoietin after solid organ transplantation Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_8): viii47 - viii49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cote, M. D. Zilberberg, S. H. Mody, L. J. Dordelly, and B. Celli Haemoglobin level and its clinical impact in a cohort of patients with COPD Eur. Respir. J., May 1, 2007; 29(5): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ponikowski, S. D. Anker, J. Szachniewicz, D. Okonko, M. Ledwidge, R. Zymlinski, E. Ryan, S. M. Wasserman, N. Baker, D. Rosser, et al. Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial J. Am. Coll. Cardiol., February 20, 2007; 49(7): 753 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Nanas, C. Matsouka, D. Karageorgopoulos, A. Leonti, E. Tsolakis, S. G. Drakos, E. P. Tsagalou, G. D. Maroulidis, G. P. Alexopoulos, J. E. Kanakakis, et al. Etiology of Anemia in Patients With Advanced Heart Failure J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2485 - 2489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J D Newton and I B Squire Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure Heart, October 1, 2006; 92(10): 1441 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hammerman-Rozenberg, J. M. Jacobs, D. Azoulay, and J. Stessman Aspirin prophylaxis and the prevalence of anaemia Age Ageing, September 1, 2006; 35(5): 514 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Komajda, S. D. Anker, A. Charlesworth, D. Okonko, M. Metra, A. Di Lenarda, W. Remme, C. Moullet, K. Swedberg, J. G.F. Cleland, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET Eur. Heart J., June 2, 2006; 27(12): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF]
|
|
|
|
|
|
M. Cladellas, J. Bruguera, J. Comin, J. Vila, E. de Jaime, J. Marti, and M. Gomez Is pre-operative anaemia a risk marker for in-hospital mortality and morbidity after valve replacement? Eur. Heart J., May 1, 2006; 27(9): 1093 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, C. C. Lang, S. D. Roger, J. B. Young, S. D. Solomon, C. B. Granger, J. Ostergren, et al. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Circulation, February 21, 2006; 113(7): 986 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Opasich, M. Cazzola, L. Scelsi, S. De Feo, E. Bosimini, R. Lagioia, O. Febo, R. Ferrari, A. Fucili, R. Moratti, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure Eur. Heart J., November 1, 2005; 26(21): 2232 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Okonko, D. J. Van Veldhuisen, P. A. Poole-Wilson, and S. D. Anker Anaemia of chronic disease in chronic heart failure: the emerging evidence Eur. Heart J., November 1, 2005; 26(21): 2213 - 2214. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kosiborod, J. P. Curtis, Y. Wang, G. L. Smith, F. A. Masoudi, J. M. Foody, E. P. Havranek, and H. M. Krumholz Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project Arch Intern Med, October 24, 2005; 165(19): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|